Impact of weight-loss medications on the cardiovascular system: Focus on current and future anti-obesity drugs

American Journal of Cardiovascular Drugs

Volumn 7, Issue 4, 2007, Pages 273-288

  Drolet, Benoit ^a,b   Simard, Chantale ^a,b   Poirier, Paul ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ALBUGON; ANANDAMIDE; ANTIOBESITY AGENT; AVE 0010; BIM 22103; CANNABINOID; CANNABINOL; CANNABIS; CBT 1452; CJC 1131; CP 368296; CS 872; CYCLOSPORIN; DEXANABINOL; DEXFENFLURAMINE; DRONABINOL; ENZYME ACTIVATOR; ERGOTAMINE; EXENDIN 4; FENFLURAMINE; GC 1; GLYCOSYLTRANSFERASE INHIBITOR; HORMONE RECEPTOR STIMULATING AGENT; IBROLIPIM; INCRETIN; INGLIFORIB; KB 141; LIRAGLUTIDE; LY 307161; LY 548806; MB 243; MELANOCORTIN 4 RECEPTOR AGONIST; NNC 70619; PHENTERMINE; PHENTOLAMINE; PROPRANOLOL; PT 15; PT 201; RESERPINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TH 0318; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA VALVE REGURGITATION; ATHEROSCLEROSIS; BODY WEIGHT; CANCER; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COMORBIDITY; COUNSELING; DIARRHEA; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; HYPERTENSION; MITRAL VALVE REGURGITATION; MUSCLE CRAMP; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 34548063168     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707040-00005     Document Type: Review

References (234)

1. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-67
2. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918
3. From the Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. JAMA 1997; 278: 1729-31
4. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8
5. Weissman NJ, Tighe JFJ, Gottdiener JS, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998; 339: 725-32
6. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713-8
7. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16
8. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92: 790-5
9. Redfield MM, Nicholson WJ, Edwards WD, et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117: 50-2
10. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000; 57: 75-81
11. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxy-tryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006; 113: 81-9
12. Rajamani S, Studenik C, Lemmens-Gruber R, et al. Cardiotoxic effects of fenfluramine hydrochloride on isolated cardiac preparations and ventricular myocytes of guinea-pigs. Br J Pharmacol 2000; 129: 843-52
13. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63: 1223-9
14. Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999; 7: 313-22
15. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719-24
16. Weissman NJ, Panza JA, Tighe JF, et al. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 267-73
17. Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134: 261-6
18. Cannistra LB, Cannistra AJ. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment [letter]. N Engl J Med 1998; 339: 771
19. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703-9
20. Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286: 2011-4
21. Palmieri V, Arnett DK, Roman MJ, et al. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Am J Med 2002; 112: 710-5
22. Davidoff R, McTiernan A, Constantine G, et al. Echocardiographic examination of omen previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161: 1429-36
23. Weissman NJ, Panza JA, Tighe JF, et al. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 267-73
24. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-124
25. Lechin F, van der DB, Hernandez G, et al. Neurochemical, neuroautonomic and neuropharmacological acute effects of sibutramine in healthy subjects. Neurotoxicology 2006; 27: 184-91
26. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26: 1027-48
27. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003
28. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group -Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-25
29. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363-9
30. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508-15
31. Guven A, Koksal N, Cetinkaya A, et al. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004; 6: 50-5
32. de Simone G, Romano C, De Caprio C, et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 2005; 15: 24-30
33. Atkinson RL. Use of drugs in the treatment of obesity. Annu Rev Nutr 1997; 17: 383-403
34. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459-65
35. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307-8
36. Deitel M. Sibutramine warning: hypertension and cardiac arrhythmias reported [letter]. Obes Surg 2002; 12: 422
37. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5-11
38. Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002; 16: 13-9
39. Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005; 99: 481-2
40. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 Suppl. 3: S12-23
41. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996; 36: 647-53
42. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-8
43. Sekuri C, Tavli T, Avsar A, et al. The acute effect of orlistat on endothelial function in young obese women. Int J Clin Pharmacol Res 2003; 23: 111-7
44. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-72
45. O'Donovan D, Horowitz M, Russo A, et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004; 47: 2208-14
46. Beck-da-Silva L, Higginson L, Fraser M, et al. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005; 11: 118-23
47. Nagele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999; 55: 667-9
48. Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000; 342: 1141-2
49. Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000; 70: 1541-2
50. Senechal M, Lemieux I, Beucler I, et al. Features of the metabolic syndrome of 'hypertriglyceridemic waist' and transplant coronary artery disease. J Heart Lung Transplant 2005; 24: 819-26
51. Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13
52. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4
53. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5
54. Ford WR, Honan SA, White R, et al. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 2002; 135: 1191-8
55. Bonz A, Laser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003; 41: 657-64
56. Batkai S, Pacher P, Jarai Z, et al. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 2004; 287: H595-600
57. Pacher P, Batkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 2004; 558: 647-57
58. Randall MD, Kendall DA. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 1997; 335: 205-9
59. Maccarrone M, Lorenzon T, Bari M, et al. Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J Biol Chem 2000; 275: 31938-45
60. Stefano GB, Salzet M, Bilfinger TV. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. J Cardiovasc Pharmacol 1998; 31: 862-8
61. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84
62. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61
63. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45
64. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 1999; 96: 14136-41
65. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9
66. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998; 38: 179-200
67. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98: 3662-5
68. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4
69. Leggett JD, Aspley S, Beckett SR, et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 2004; 141: 253-62
70. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 2005; 146: 809-16
71. Fimiani C, Mattocks D, Cavani F, et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal 1999; 11: 189-93
72. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 1996; 271: 19238-42
73. Varga K, Lake K, Martin BR, et al. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995; 278: 279-83
74. Hu CP, Li NS, Peng J, et al. Involvement of vanilloid receptors in heat stress-induced delayed protection against myocardial ischemia-reperfusion injury. Neuropeptides 2003; 37: 233-8
75. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7
76. Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol 2005; 69: 1705-13
77. Gebremedhin D, Lange AR, Campbell WB, et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276: H2085-93
78. Sugiura T, Kodaka T, Kondo S, et al. Inhibition by 2- arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 1997; 233: 207-10
79. Lamontagne D, Lepicier P, Lagneux C, et al. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch Mal Coeur Vaiss 2006; 99: 242-6
80. Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 2001; 132: 793-6
81. Pacher P, Batkai S, Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 2004; 558: 647-57
82. Bouchard JF, Lepicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 2003; 72: 1859-70
83. Wang Y, Liu Y, Ito Y, et al. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 2001; 294: 73-82
84. Gorelick DA, Heishman SJ, Preston KL, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 2006; 151: 754.e1-5
85. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-6
86. Hiley CR, Ford WR. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 2004; 79: 187-205
87. Joyeux M, Arnaud C, Godin-Ribuot D, et al. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 2002; 55: 619-25
88. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, et al. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 2001; 131: 523-5
89. Lepicier P, Bouchard JF, Lagneux C, et al. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003; 139: 805-15
90. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6
91. Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic myocardium: involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992; 107: 648-52
92. Szilvassy Z, Ferdinandy P, Bor P, et al. Ventricular overdrive pacing-induced anti-ischemic effect: a conscious rabbit model of preconditioning. Am J Physiol 1994; 266: H2033-41
93. Di Filippo C, Rossi F, Rossi S, et al. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 2004; 75: 453-9
94. Ribuot C, Lamontagne D, Godin-Ribuot D. Cardiac and vascular effects of cannabinoids: toward a therapeutic use? [in French]. Ann Cardiol Angeiol (Paris) 2005; 54: 89-96
95. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001; 38: 2048-54
96. Lagneux C, Adam A, Lamontagne D. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol 2003; 3: 1511-8
97. Landsman RS, Burkey TH, Consroe P, et al. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997; 334: R1-2
98. Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002
99. MacLennan SJ, Reynen PH, Kwan J, et al. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 1998; 124: 619-22
100. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202
101. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64
102. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103: 2805-9
103. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124: 200-3
104. Petronis KR, Anthony JC. An epidemiologic investigation of marijuana- and cocaine-related palpitations. Drug Alcohol Depend 1989; 23: 219-26
105. Kosior DA, Filipiak KJ, Stolarz P, et al. Paroxysmal atrial fibrillation following marijuana intoxication: a two-case report of possible association. Int J Cardiol 2001; 78: 183-4
106. Singh GK. Atrial fibrillation associated with marijuana use. Pediatr Cardiol 2000; 21: 284
107. Benowitz NL, Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion: effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther 1977; 21: 336-42
108. Pars HG, Howes JF. Potential therapeutic agents derived from the cannabinoid nucleus. Adv Drug Res 1977; 11: 97-189
109. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975; 18: 287-97
110. Kanakis Jr C, Pouget JM, Rosen KM. The effects of delta-9- tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 1976; 53: 703-7
111. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42: 58S-63S
112. Kanakis C, Pouget M, Rosen KM. Lack of cardiovascular effects of delta-9-tetrahydrocannabinol in chemically denervated men. Ann Intern Med 1979; 91: 571-4
113. Gash A, Karliner JS, Janowsky D, et al. Effects of smoking marihuana on left ventricular performance and plasma norepinephrine: studies in normal men. Ann Intern Med 1978; 89: 448-52
114. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974; 291: 65-7
115. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97
116. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34
117. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America. A randomized controlled trial. JAMA 2006; 295: 761-75
118. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72
119. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99: 578-88
120. King LM, Opie LH. Glucose and glycogen utilisation in myocardial ischemia: changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998; 180: 3-26
121. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213: 263-76
122. Dennis SC, Gevers W, Opie LH. Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol 1991; 23: 1077-86
123. Liu B, Clanachan AS, Schulz R, et al. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996; 79: 940-8
124. Tracey WR, Treadway JL, Magee WP, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol 2004; 286: H1177-84
125. Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res 2004; 36: 742-6
126. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40
127. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7: 467-77
128. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-7
129. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35
130. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91
131. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100
132. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266: E459-66
133. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52
134. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242-52
135. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004; 36: 842-5
136. Nickola MW, Wold LE, Colligan PB, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 2000; 36: 501-5
137. Illiano G, Naviglio S, Pagano M, et al. Leptin affects adenylate cyclase activity in H9c2 cardiac cell line: effects of short- and long-term exposure. Am J Hypertens 2002; 15: 638-43
138. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-9
139. Rajapurohitam V, Gan XT, Kirshenbaum LA, et al. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003; 93: 277-9
140. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5
141. Bray GA, York DA. Clinical review 90: leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82: 2771-6
142. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-8
143. Sader S, Nian M, Liu P. Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 2003; 108: 644-6
144. Sweeney G. Leptin signalling. Cell Signal 2002; 14: 655-63
145. Wold LE, Relling DP, Duan J, et al. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 2002; 39: 69-74
146. Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75
147. Collins S, Daniel KW, Rohlfs EM, et al. Impaired expression and functional activity of the beta 3- and beta 1-adrenergic receptors in adipose tissue of congenitally obese (C57BL/6J ob/ob) mice. Mol Endocrinol 1994; 8: 518-27
148. Collins S, Surwit RS. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog Horm Res 2001; 56: 309-28
149. Bachman ES, Dhillon H, Zhang CY, et al. BetaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297: 843-5
150. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82: I12-25
151. Minhas KM, Khan SA, Raju SV, et al. Leptin repletion restores depressed {beta}-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. J Physiol 2005; 565: 463-74
152. Tsutsumi K. Lipoprotein lipase and atherosclerosis. Curr Vasc Pharmacol 2003; 1: 11-7
153. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060-8
154. Tsutsumi K, Inoue Y, Shima A, et al. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 1993; 92: 411-7
155. Kern PA, Ong JM, Saffari B, et al. The effects of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans. N Engl J Med 1990; 322: 1053-9
156. Sadur CN, Yost TJ, Eckel RH. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 1984; 59: 1176-82
157. Levak-Frank S, Radner H, Walsh A, et al. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest 1995; 96: 976-86
158. Jensen DR, Schlaepfer IR, Morin CL, et al. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am J Physiol 1997; 273: R683-9
159. Kusunoki M, Hara T, Tsutsumi K, et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia 2000; 43: 875-80
160. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-41
161. Fan W, Boston BA, Kesterson RA, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385: 165-8
162. Giraudo SQ, Billington CJ, Levine AS. Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands. Brain Res 1998; 809: 302-6
163. Nordheim U, Nicholson JR, Dokladny K, et al. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats. Peptides 2006; 27: 438-43
164. Davignon J. Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab 1995; 21: 139-46
165. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81: 1097-142
166. Engler H, Riesen WF. Effect of thyroid function on concentrations of li-poprotein(a). Clin Chem 1993; 39: 2466-9
167. de Bruin TW, van Barlingen H, Linde-Sibenius TM, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. J Clin Endocrinol Metab 1993; 76: 121-6
168. Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993; 14: 184-93
169. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9
170. Forrest D, Vennstrom B. Functions of thyroid hormone receptors in mice. Thyroid 2000; 10: 41-52
171. Wikstrom L, Johansson C, Salto C, et al. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 1998; 17: 455-61
172. Johansson C, Vennstrom B, Thoren P. Evidence that decreased heart rate in thyroid hormone receptor-alpha1-deficient mice is an intrinsic defect. Am J Physiol 1998; 275: R640-6
173. Gloss B, Trost S, Bluhm W, et al. Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology 2001; 142: 544-50
174. Schwartz HL, Strait KA, Ling NC, et al. Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J Biol Chem 1992; 267: 11794-9
175. Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-64
176. Ribeiro MO, Carvalho SD, Schultz JJ, et al. Thyroid hormone: sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. J Clin Invest 2001; 108: 97-105
177. Weiss RE, Murata Y, Cua K, et al. Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice. Endocrinology 1998; 139: 4945-52
178. Ye L, Li YL, Mellstrom K, et al. Thyroid receptor ligands: 1. Agonist ligands selective for the thyroid receptor beta1. J Med Chem 2003; 46: 1580-8
179. Iossa S, Liverini G, Barletta A. Relationship between the resting metabolic rate and hepatic metabolism in rats: effect of hyperthyroidism and fasting for 24 hours. J Endocrinol 1992; 135: 45-51
180. Oppenheimer JH, Schwartz HL, Lane JT, et al. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 1991; 87: 125-32
181. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003; 100: 10067-72
182. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
183. Zhang C, Hein TW, Wang W, et al. Activation of JNK and xanthine oxidase
184. Zhang C, Xu X, Potter BJ, et al. TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2006; 26: 475-80
185. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: H742-8
186. Verges B. Clinical interest of PPARs ligands. Diabetes Metab 2004; 30: 7-12
187. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-7
188. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006; 99: 69-77
189. Wang X, Feuerstein GZ, Xu L, et al. Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 2004; 65: 890-6
190. Kalra SP, Dube MG, Pu S, et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100
191. Billington CJ, Briggs JE, Harker S, et al. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994; 266: R1765-70
192. Broberger C, Landry M, Wong H, et al. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997; 66: 393-408
193. Stricker-Krongrad A, Kozak R, Burlet C, et al. Physiological regulation of hypothalamic neuropeptide Y release in lean and obese rats. Am J Physiol 1997; 273: R2112-6
194. Wilding JP, Gilbey SG, Mannan M, et al. Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. J Endocrinol 1992; 132: 299-304
195. Harland D, Bennett T, Gardiner SM. Cardiovascular actions of neuropeptide Y in the hypothalamic paraventricular nucleus of conscious Long Evans and Brattleboro rats. Neurosci Lett 1988; 85: 239-43
196. van Dijk G, Bottone AE, Strubbe JH, et al. Hormonal and metabolic effects of paraventricular hypothalamic administration of neuropeptide Y during rest and feeding. Brain Res 1994; 660: 96-103
197. VanNess JM, DeMaria JE, Overton JM. Increased NPY activity in the PVN contributes to food-restriction induced reductions in blood pressure in aortic coarctation hypertensive rats. Brain Res 1999; 821: 263-9
198. Carter DA, Vallejo M, Lightman SL. Cardiovascular effects of neuropeptide Y in the nucleus tractus solitarius of rats: relationship with noradrenaline and vaso-pressin. Peptides 1985; 6: 421-5
199. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50: 143-50
200. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070-7
201. Pedersen-Bjergaard U, Host U, Kelbaek H, et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 1996; 56: 497-503
202. Keire DA, Bowers CW, Solomon TE, et al. Structure and receptor binding of PYY analogs. Peptides 2002; 23: 305-21
203. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-4
204. Nordheim U, Hofbauer KG. Stimulation of NPY Y2 receptors by PYY3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens. Am J Physiol Regul Integr Comp Physiol 2004; 286: R138-42
205. Beck B, Jhanwar-Uniyal M, Burlet A, et al. Rapid and localized alterations of neuropeptide Y in discrete hypothalamic nuclei with feeding status. Brain Res 1990; 528: 245-9
206. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7
207. Kopelman PG. Hormones and obesity. Baillieres Clin Endocrinol Metab 1994; 8: 549-75
208. Jessop DS, Dallman MF, Fleming D, et al. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-14
209. Rebuffe-Scrive M, Bronnegard M, Nilsson A, et al. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 1990; 71: 1215-9
210. Stewart PM, Tomlinson JW. Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 2002; 13: 94-6
211. Seckl JR, Morton NM, Chapman KE, et al. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004; 59: 359-93
212. Livingstone DE, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-3
213. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70
214. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90
215. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-27
216. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349: 1210-3
217. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-21
218. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-6
219. Paulmyer-Lacroix O, Boullu S, Oliver C, et al. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-5
220. Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002; 87: 5630-5
221. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003; 88: 2738-44
222. Walker BR, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin Ther Targets 2003; 7: 771-83
223. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45: 1528-32
224. Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003; 144: 4755-62
225. Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995; 80: 3155-9
226. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 285-91
227. Livingstone DE, Walker BR. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003; 305: 167-72
228. Sandeep TC, Andrew R, Homer NZ, et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005; 54: 872-9
229. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-27
230. Nosadini R, Del Prato S, Tiengo A, et al. Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 1983; 57: 529-36
231. Page R, Boolell M, Kalfas A, et al. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in Cushing's disease: a minimal model analysis. Clin Endocrinol (Oxf) 1991; 35: 509-17
232. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-33
233. Glorioso N, Filigheddu F, Parpaglia PP, et al. 11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension. Eur Heart J 2005; 26: 498-504
234. Sheppard KE. Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart. Vitam Horm 2003; 66: 77-112